SCHEMBL4288930

SCHEMBL4288930

CCCCCC(=O)OCCCc1ccc(O)c(OC)c1

nearest known ligand 0.73

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.67
CYP3A4 P08684 3/20 0.67
CYP2C9 P11712 3/20 0.67
CYP2C19 P33261 3/20 0.67
CYP2C8 P10632 2/20 0.67
CYP2B6 P20813 2/20 0.67
TRPV1 Q8NER1 6/20 0.64
HTR1A P08908 3/20 0.59
CYP2D6 P10635 2/20 0.59
CYP2E1 P05181 1/20 0.59
ALOX5 P09917 1/20 0.59
LTA4H P09960 1/20 0.59
CYP2A6 P11509 1/20 0.59
ALDH1A1 P00352 1/20 0.58
HPGD P15428 1/20 0.58
ALOX15 P16050 1/20 0.58
BLM P54132 1/20 0.58
PMP22 Q01453 1/20 0.58
MET P08581 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11936829 0.93 CYP1A2 (0.71) CYP1A2CYP3A4CYP2C9CYP2C19CYP2C8
SCHEMBL21034088 0.90 CYP3A4 (0.71) CYP1A2CYP3A4CYP2C9CYP2C19CYP2C8
SCHEMBL22493033 0.90 CYP3A4 (0.67) CYP1A2CYP3A4CYP2C9CYP2C19CYP2C8
SCHEMBL4284084 0.87 CYP3A4 (0.60) CYP1A2CYP3A4CYP2C9CYP2C19CYP2C8
SCHEMBL28359747 0.87 CYP3A4 (0.74) CYP1A2CYP3A4CYP2C9CYP2C19CYP2C8
SCHEMBL4288224 0.86 CYP3A4 (0.62) CYP1A2CYP3A4CYP2C9CYP2C19CYP2C8
SCHEMBL4289118 0.86 CYP3A4 (0.62) CYP1A2CYP3A4CYP2C9CYP2C19CYP2C8
SCHEMBL6583008 0.86 ALOX5 (0.62) CYP1A2CYP3A4CYP2C9CYP2C19CYP2C8
SCHEMBL3123447 0.86 TRPV1 (0.67) CYP1A2CYP3A4CYP2C9CYP2C19CYP2C8
SCHEMBL14503249 0.86 ALOX5 (0.58) CYP1A2CYP3A4CYP2C9CYP2C19CYP2C8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765809-B2 Ester derivative and use thereof AJINOMOTO CO., INC. (JP) 2014-07-01 US disclosed
US-20130053441-A1 NOVEL ESTER DERIVATIVE AND USE THEREOF AJINOMOTO CO., INC. (JP) 2013-02-28 US disclosed
US-8212068-B2 Ester derivative and use thereof AJINOMOTO CO., INC. (JP) 2012-07-03 US disclosed
US-20090170942-A1 ESTER DERIVATIVE AND USE THEREOF AJINOMOTO CO. INC (JP) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053441-A1 NOVEL ESTER DERIVATIVE AND USE THEREOF MEP1A, CES2, MEP1B CYP1A2 188/4885CYP3A4 472/4885CYP2C9 645/4885
US-20090170942-A1 ESTER DERIVATIVE AND USE THEREOF MEP1A, CES2, F8 CYP1A2 148/4885CYP3A4 502/4885CYP2C9 568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.